Proprietary AI analyst is now available
- Public Comps
- Rise
Rise Valuation Multiples
Discover Rise's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Pilulka Lekarny, SC Ropharma, Wellgistics Health, Farmacosmo and more.
Rise Overview
About Rise
Rise Inc is engaged in real estate business. The operations of the company include development of real estate and rental of real estate. The company conduct business to develop hotels, condominiums, residential properties, and commercial facilities.
Founded
1947
HQ

Employees
3
Website
Sectors
Financials (LTM)
EV
$13M
Valuation Multiples
Start free trialRise Financials
Rise reported last 12-month revenue of $3M.
In the same LTM period, Rise generated $315K in net income.
Rise P&L
In the most recent fiscal year, Rise reported revenue of $2M and EBITDA of $644K.
Rise is profitable as of last fiscal year, with gross margin of 84%, EBITDA margin of 27%, and net margin of 2%.
Financial data powered by Morningstar, Inc.
Rise Stock Performance
Rise has current market cap of $15M, and enterprise value of $13M.
Market Cap Evolution
Rise's stock price is $0.16.
Rise share price increased by 6.8% in the last 30 days.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $15M | -0.1% | 6.8% | - | - | $0.00 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRise Valuation Multiples
Rise trades at 4.6x EV/Revenue multiple, and 19.6x EV/EBITDA.
Rise Financial Valuation Multiples
As of June 24, 2026, Rise has market cap of $15M and EV of $13M.
Rise has a P/E ratio of 49.1x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Rise Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Rise Margins & Growth Rates
Rise grew revenue by 15% and net profit by 465% in the last fiscal year.
In the most recent fiscal year, Rise reported gross margin of 84%, EBITDA margin of 27%, and net margin of 2%.
Rise Margins
Rise Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Rise Operational KPIs
Rise's revenue per employee in the last FY averaged $0.8M, while opex per employee averaged $0.6M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Rise Competitors
Rise competitors include Pilulka Lekarny, SC Ropharma, Wellgistics Health, Farmacosmo, PetMeds, BlueMTec, Talea Group, d1000, MARX Biotech and Fangzhou.
Most Rise public comparables operate across Pharmacies.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 0.4x | - | 27.7x | - | |||
| 0.2x | - | 4.4x | - | |||
| 1.6x | - | (0.4x) | - | |||
| 0.5x | - | 78.8x | - | |||
| 0.1x | 0.1x | (0.8x) | (0.6x) | |||
| 0.5x | - | 76.3x | - | |||
| 0.6x | - | 24.4x | - | |||
| 0.3x | - | 4.1x | - | |||
This data is available for Pro users. Sign up to see all Rise competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Rise
Rise has acquired 1 company to date.
Last acquisition by Rise was on March 1st 2026. Rise acquired Passmed for undisclosed valuation.
Latest Acquisitions by Rise
| Description | Passmed is a Japanese provider of education and training for pharmacists and students. Operations include new drug information distribution and matching services. |
| HQ Country | |
| HQ City | Amagasaki |
| Deal Date | 1 Mar 2026 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Rise acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Rise
| When was Rise founded? | Rise was founded in 1947. |
| Where is Rise headquartered? | Rise is headquartered in Japan. |
| How many employees does Rise have? | As of today, Rise has over 3 employees. |
| Is Rise publicly listed? | Yes, Rise is a public company listed on Tokyo Stock Exchange. |
| What is the stock symbol of Rise? | Rise trades under 8836 ticker. |
| When did Rise go public? | Rise went public in 1972. |
| Who are competitors of Rise? | Rise main competitors include Pilulka Lekarny, SC Ropharma, Wellgistics Health, Farmacosmo, PetMeds, BlueMTec, Talea Group, d1000, MARX Biotech, Fangzhou. |
| What is the current market cap of Rise? | Rise's current market cap is $15M. |
| What is the current revenue of Rise? | Rise's last 12 months revenue is $3M. |
| What is the current revenue growth of Rise? | Rise revenue growth (vs. last FY) is 15%. |
| What is the current EV/Revenue multiple of Rise? | Current revenue multiple of Rise is 4.6x. |
| What is the current net income of Rise? | Rise's last 12 months net income is $315K. |
| How many companies Rise has acquired to date? | As of June 2026, Rise has acquired 1 company. |
| What was the largest acquisition by Rise? | None of the M&A deals Rise has completed have disclosed valuations. |
| What companies Rise acquired? | Rise acquired Passmed. |
| In how many companies Rise has invested to date? | Rise hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Rise
Lists including Rise
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.
